Mozambique vs New Zealand: Prevalence rate of hypertension in men aged 30-79
Mozambique
34.3
in 2019
New Zealand
34.4
in 2019
Mozambique rank
136th
New Zealand rank
133rd
Prevalence rate of hypertension in men aged 30-79 over time
- Mozambique
- New Zealand
How they compare
New Zealand currently reports 34.4 against 34.3 in Mozambique, a difference of 0.1.
The two have swapped places 2 times across 30 shared years of data; in 1990 it was New Zealand ahead.
Mozambique ranks 136th and New Zealand ranks 133rd of 195 countries.
Across the 3 decades both report, Mozambique averaged higher in 2 and New Zealand in 1.
Head to head by decade
| Decade | Mozambique | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 36.37 | 36.68 | 0.31 | New Zealand |
| 2000s | 37.88 | 35.85 | 2.03 | Mozambique |
| 2010s | 36.2 | 34.93 | 1.27 | Mozambique |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Mozambique or New Zealand?
- New Zealand, at 34.4 against 34.3 in Mozambique as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Mozambique and New Zealand?
- 0.1, with New Zealand ahead.
- How many years of comparable data are there for Mozambique and New Zealand?
- 30 years are reported by both, from 1990 to 2019.
- How do Mozambique and New Zealand rank globally for prevalence rate of hypertension in men aged 30-79?
- Mozambique ranks 136th and New Zealand ranks 133rd of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.